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H I G H L I G H T S
 Botulinum toxin B increases spontaneous muscle activity after 1 day incubation.
 Rocuronium bromide reduces spontaneous muscle activity.
 Application of glutamate receptor antagonists similarly increase muscle activity.
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A B S T R A C T
In organotypic spinal cord–skeletal muscle co-cultures, motoneurons are driven by locomotor
commands and induce contractions in surrounding muscle ﬁbres. Using these co-cultures, it has been
shown that effects of organophosphorus compounds on neuromuscular synapses can be determined in
vitro. In the present study we aimed to extend this in vitro tool for pharmacologic testing of botulinum
toxin B. This neurotoxin is widely used for the treatment of dystonia. Besides its effects on the
neuromuscular junction, botulinum toxins may also act at centrally located synapses. Incubation with
botulinum toxin B (Neurobloc1) induced a signiﬁcant increase in muscular activity after 24, 48 and 72 h.
Application of the NMDA- and AMPA-receptor antagonists AP5 (20 mM) and CNQX (15 mM) induced a
similar augmentation of muscle activity after 48 and 72 h, respectively. Administration of the glycine- and
GABA(A)-receptor antagonists strychnine (1 mM) and bicuculline (100 mM) did not alter intrinsic muscle
activity. In contrast, application of a non-depolarizing muscle relaxant rocuronium bromide reduced the
muscle activity in a dose-dependent manner. Our ﬁndings suggest that glutamatergic synapses in the
spinal cord are more sensitive to botulinum toxin B than synaptic contacts between spinal motoneurons
and muscle ﬁbres.
ã 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
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Botulinum toxin is a food-borne poison produced by the
bacterium Clostridium botulinum, which induces ﬂaccid paralysis
when injected in muscles for the treatment of medical conditions
such as torticollis or spasticity (Dressler, 2010). However, an
overdose of botulinum toxins may lead to asphyxia by inhibition of
respiratory muscles (Souayah et al., 2006; Williams et al., 2014;* Corresponding author at: Experimental Anesthesiology Section, Department of
Anesthesiology and Intensive Care Medicine, Eberhard-Karls-University, Wald-
hörnlestrasse 22, D-72072 Tübingen, Germany.
E-mail address: veit-simon.eckle@uni-tuebingen.de (V.-S. Eckle).
http://dx.doi.org/10.1016/j.toxlet.2015.08.003
0378-4274/ã 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open acceWitoonpanich et al., 2010). Before use of botulinum toxins for
medical purposes, the potency and the high toxicity need to be
determined. The commonly used method for potency testing of
botulinum toxins is the mouse LD50 assay (lethal dose that kills 50%
of the tested animals). This LD50 assay inﬂicts severe suffering to
the mice and may lead to suffocation within the test period (Adler
et al., 2010; Bitz, 2010). Thus, alternatives to this animal testing
that reduce the number of animals or replace the detection method
with an in vitro assay are strongly encouraged by legal authorities
(Adler et al., 2010; Council of Europe, 2011). Eight different
serotypes of botulinum toxin (A–H) are described so far (Barash
and Arnon, 2014; Dover et al., 2014; Humeau et al., 2000; Schiavo
et al., 2000). Currently, botulinum toxins A and B are in medical use
(Dressler, 2010; Schiavo et al., 2000). Both neurotoxins are thoughtss article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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(Rossetto et al., 2001). However, botulinum toxin A and B display
two different molecular mechanisms of action: While botulinum
toxin A cleaves the synaptosomal-associated protein of 25 kDa
(SNAP-25), botulinum toxin B induces cleavage of the vesicle-
associated membrane protein 2 (VAMP-2) (Schiavo et al., 2000).
Besides its action on neuromuscular junctions, it was shown that
botulinum toxin B acts at central synapses to inhibit neurotrans-
mitter release (Höltje et al., 2013 McMahon et al., 1992; Tighe and
Schiavo, 2013).
Lately, an animal-free potency testing assay for botulinum toxin
A has been approved by the FDA, Health Canada, and the European
Union (Fernández-Salas et al., 2012). By contrast, no alternative
method is approved for potency testing of botulinum B so far.
Hitherto, we described an in vitro assay to determine long-term
effects of organophosphorus compounds and botulinum toxin A
(Drexler et al., 2011; Eckle et al., 2014). In the present study, we
investigated the effect of botulinum toxin B on intrinsic muscle
activity in organotypic spinal cord–skeletal muscle co-cultures.
This muscle activity is driven by locomotor activity arising from the
spinal ventral horn and can be suppressed by organophosphorus
compounds or a depolarizing muscle relaxant (Drexler et al., 2013,
2011). These co-cultures are well suitable to investigate long-term
effects of drugs on excitatory, inhibitory and neuromuscular
synaptic transmission (Streit et al., 1991). In our experiments,
organotypic co-cultures were incubated with botulinum toxin B for
3 subsequent days and intrinsic muscle activity was measured at
intervals of 24 h. Similar experiments were conducted with a non-
depolarizing muscle relaxant to block the neuromuscular junction,Fig. 1. Detection method of muscle activity. Using videomicroscopy, muscle ﬁbers of an
DIV 13. Intrinsic muscle activity was quantiﬁed as a change in brightness of pixels in the r
scale. Using a threshold (red dotted line), the frequency of muscle contractions could be
interest (blue frame) was re-identiﬁed (C) and intrinsic muscle activity was quantiﬁedwith NMDA- and AMPA-receptor antagonists to inhibit the
excitatory signaling, and with GABA(A)- and glycine-receptor
antagonists to impede the inhibitory neurotransmission in a long-
term setting.
2. Material and methods
2.1. Spinal cord–skeletal muscle co-cultures
This study was carried out in strict accordance with the
regulations, policies, and principles of the NIH Guide for the Care
and Use of Laboratory Animals. Brieﬂy, all procedures were
performed in accordance with the German Animal Welfare
Regulations (TierSchG), were reviewed by the Institutional Animal
Care and Use Committee (Einrichtung für Tierschutz, Tierärztli-
chen Dienst und Labortierkunde, Eberhard-Karls-University,
Tübingen, Germany), and approved by the Government (Regier-
ungspräsidium Tübingen, Tübingen, Germany). All efforts were
made to minimize suffering. For tissue harvesting, C57/BL6J mice
were decapitated under deep isoﬂurane anesthesia. Tissue slices
derived from the spinal cord and surrounding muscles were
prepared as previously described (Drexler et al., 2011). Embryonic
spinal columns (day E 13) were cut transversely into 300 mm thick
slices using a microslicer (NVSLM1, World Precision Instruments,
Sarasota, FL, USA). Slices from the spinal cord and surrounding
muscle tissue were glued onto glass coverslips by clotting of
chicken plasma and thrombin (Sigma, Taufkirchen, Germany). The
coverslips were put into plastic tubes containing nutrient ﬂuid
(0.75 mL) and 10 nM neuronal growth factor (from Sigma). A roller organotypic spinal cord-skeletal muscle co-culture were monitored from DIV 10 to
egion of interest (blue frame; A). These changes in brightness were plotted on a time
 detected (B). After 24 h incubation with Neurobloc1 (20 U/mL) the same region of
 (D) as described above. Note the increase in muscle activity between (B) and (D).
V.-S. Eckle et al. / Toxicology Letters 244 (2016) 167–171 169tube technique was used to culture the tissue as ﬁrst described by
Gähwiler (1981). After 1 day in culture, antimitotics (10 mM 5-
ﬂuoro-2-deoxyuridine, 10 mM cytosine-b-D-arabino-furanoside,
10 mM uridine; all from Sigma) were added to reduce proliferation
of glial cells. Nutrient ﬂuid (100 mL) consisted of 25 mL horse
serum (Invitrogen, Karlsruhe, Germany), 25 mL Hanks’ balanced
salt solution (Sigma), 50 mL basal medium Eagle (Sigma), 1 mL 50%
glucose, and 0.5 mL L-glutamine (200 mM). Nerve–muscle co-
cultures typically were used after 10 days in vitro (DIV) for
recording of intrinsic muscle activity.
2.2. Experimental procedure
Neurobloc1 (5000 U/ml, Eisai GmbH, Frankfurt, Germany) was
used to test the effects of botulinum toxin B on organotypic spinal
cord–skeletal muscle co-cultures in vitro. Intrinsic muscle activity
in nerve–muscle co-cultures was recorded on three subsequent
days (DIV 10–13). To exclude intrinsic changes in muscle activity
over the period of investigation, the drug application group was
compared with a sham group, which was treated similarly but did
not receive the respective drug application. For videomicroscopic
recordings, a plastic tube containing spinal cord–skeletal muscleFig. 2. Botulinum toxin B increases muscle activity. 20 and 1000 U/mL Neurobloc1 (N
skeletal muscle co-cultures in all three consecutive days of investigation. The medians
relaxant rocuronium bromide (ROC) signiﬁcantly reduced the muscle activity at a con
signiﬁcance until after 72 h of incubation, possibly due to plasticity mechanisms (F).The
antagonist strychnine (1 mM) (both included in group labeled Bicu/Stry) did not alter m
NMDA-receptor antagonist AP5 (20 mM) + the AMPA-receptor antagonist CNQX (15 mM
incubation (G). Remarkably, after 48 h of incubation, muscle contractions were signiﬁcant
not change substantially (H). The effect could be also observed after 72 h of incubation (I)
test combined with a Dunn’s multiple comparison analysis was applied for statistical testi
analyzed experiments is indicated in brackets..co-cultures was placed on an inverted light microscope (40, Carl
Zeiss Microimaging, Goettingen, Germany) as previously described
(Eckle et al., 2014). Intrinsic muscle activity was monitored before
(control condition) and after drug exposure using a video camera
(The Imaging source Europe, Bremen, Germany) at intervals of
24 h. At the beginning of each recording session, contrast and
brightness of the video image were optimized and a single picture
was taken and stored on the computer. This allowed re-
identiﬁcation of the regions of interest, which was necessary as
cultures were returned to the incubator between recording
sessions. Each recording session lasted 180 s. The frame rate was
30 Hz. As previously described (Drexler et al., 2011), changes in
brightness were averaged by an in-house developed movement
detector algorithm, written in MATLAB version 7.1 (The Math-
Works Inc., Natick, MA, USA). The calculated vector proved to be a
robust indicator of muscle contractions and was insensitive to
changes in overall picture brightness. The frequency of muscle
contractions was estimated by applying a threshold criterion to
this vector (Fig. 1). During the recordings, the temperature was
kept at 36 C with a heating system.B) signiﬁcantly increased the intrinsic muscle activity in organotypic spinal cord–
 and interquartile ranges (IQR) are presented (A–C). The non-depolarizing muscle
centration of 3 mM after 24 and 48 h incubation (D, E). This effect did not reach
 selective GABA(A)-receptor antagonist bicuculline (100 mM) + the glycine-receptor
uscle contractions in comparison with the sham-treated group (G). Similarly, the
) (group labeled AP5/CNQX) did not change intrinsic muscle activity after 24 h of
ly increased in the AP5/CNQX group, while activity in the other group (Bicu/Stry) did
. The whiskers of the box plots signify the 5th to 95th percentile. The Kruskal–Wallis
ng because the sham condition displayed not a Gaussian distribution. The number of
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Intrinsic muscle activity was quantiﬁed using a Hewlett Packard
Z800 video-workstation (Picturetools, Hamburg, Germany). One
region of interest (containing 25  25 pixels) was deﬁned per
tested co-culture by visual inspection. Close attention was paid to
those regions containing high contrast borders of muscle ﬁbres
that were moving during the course of muscle contractions. Due to
intrinsic muscle activity, the brightness of pixels (8 bit resolution)
in the region of interest changed in a time-dependent manner.
These changes correlated with the intensity and frequency of
muscle contractions (Drexler et al., 2013, 2011; Eckle et al., 2014).
Software for analyzing the data was written in Matlab 7.1 (The
MatWorks Inc., Natick, MA, USA).
2.4. Data analysis
The data sets were tested for Gaussian distribution (Graph Pad
Prism, version 5.03). The Kruskal–Wallis test, combined with a
Dunn’s multiple comparison analysis, was applied for statistical
testing of unpaired samples, assuming non-parametric data sets.
Data are presented as medians and interquartile ranges (IQR). The
whiskers of the box plots signify the 5th to 95th percentile.
Signiﬁcant p-values are indicated with asterisks (*<0.05, **<0.01,
***<0.001). Recording samples with intrinsic muscle activity
<0.3 Hz on DIV 10 were excluded from analysis.
3. Results
3.1. Botulinum toxin B increases muscle activity
Using spinal cord–skeletal muscle co-cultures, we tested the
long-term effect of botulinum toxin B on intrinsic muscle
contractions in this culture system (Fig. 1). The Video data
1 representatively shows spontaneous muscle activity obtained
from a co-culture on DIV 10 and after 24 h incubation with 20 U/mL
Neurobloc1 (Video data 2). The intrinsic muscle activity in the
sham condition (n = 60) was stable for the three consecutive days of
pharmacologic investigation with a median of 0.7 Hz (IQR 0.2–1.5),
0.6 Hz (IQR 0.2–1.2) and 0.6 Hz (IQR 0.2–1.3), respectively (Fig. 2).
The application of botulinum toxin B (20 or 1000 U/mL Neuro-
bloc1) induced a 3-fold increase in intrinsic muscle activity after
24 h of incubation, which lasted through 48 and 72 h (Fig. 2A–C).
3.2. Rocuronium bromide reduces intrinsic muscle activity
In this organotypic culture system, there are at least three
functional types of neurotransmission: inhibitory GABAergic and
glycinergic synapses, excitatory glutamatergic synapses, and
cholinergic neuromuscular junctions (Rosato-Siri et al., 2004).
Thus, we addressed the question whether chronic inhibition of one
of these synaptic transmission modes results in a similar increase
of intrinsic muscle activity as observed for botulinum toxin B. First,
we applied rocuronium bromide, which is a clinically used non-
depolarizing muscle relaxant that competitively blocks nicotinic
acetylcholine receptors at the neuromuscular junction (Mallon
et al., 2009). The application of rocuronium bromide (1 or 3 mM)
reduced the muscle activity in a concentration-dependent manner
after 24 h of incubation (Fig. 2D–F), similar to ﬁndings in rat spinal
cord–muscle cell co-cultures in vitro (Magloire and Streit, 2009;
Nishimaru et al., 2005).
3.3. Block of excitatory or inhibitory spinal network transmission
In a following step, we investigated the impact of long-term
inhibition of excitatory glutamatergic and inhibitory GABAergicand glycinergic transmission on intrinsic motoneuronal activity
(Fig. 2G–I). Application of the ionotropic NMDA-receptor antago-
nist AP5 (20 mM) plus the AMPA-receptor antagonist CNQX
(15 mM) did not change motoneuronal activity after 24 h incuba-
tion (Fig. 2G). However, after 48 and 72 h, a signiﬁcant increase in
muscular activity could be detected with these antagonists in
comparison with the sham-treated condition suggesting an
indirect mechanism (Fig. 2H–I, p < 0.01 and p < 0.001, respectively,
as determined using Kruskal–Wallis combined with Dunn’s
multiple comparison test). In contrast, inhibition of GABAergic
and glycinergic neurotransmission with administration of bicucul-
line (100 mM) plus strychnine (1 mM), respectively, did not
signiﬁcantly alter the muscle activity over a period of three days.
These results corroborate the notion that long-term disruption of
glutamatergic transmission mediated by AMPA- and NMDA-
receptors increases motoneuronal activity in young spinal cord–
skeletal muscle co-cultures.
4. Discussion
4.1. Increased muscular activity induced by botulinum toxin B
The main ﬁnding of the study is that botulinum toxin B did not
reduce neuromuscular activity as it was shown for rocuronium
bromide and as it might be anticipated coming from clinical
experiences with this drug (Schiavo et al., 2000). To the contrary,
botulinum toxin B increased motoneuronal activity as measured in
muscular output. As far as the utilized spinal cord–muscle co-
culture system also contained excitatory glutamatergic and
inhibitory glycinergic and GABAergic synapses, we suspected an
interaction with one type of this neurotransmitter system. By
applying glutamate receptor antagonists (AP5/CNQX) a similar
increase in spontaneous muscle activity as seen for botulinum
toxin B was detected. This may be related to the high expression of
the substrate of botulinum toxin B, VAMP-2 at glutamatergic
synapses (Bragina et al., 2010; Ferecskó et al., 2015). However, this
effect emerged with a slower time onset (2 days after incubation).
Recently, it could be shown that young spinal cultures (7–9 DIV)
conserved the ability to regenerate in response axonal cuts
(Heidemann et al., 2014). In our experiments, we performed a
pharmacological cut of AMPA- and NMDA-receptor-mediated
transmission or applied a neurotoxic drug and observed an
increase of muscle activity after 48 h. Given the importance of
glutamatergic transmission for ﬁctive locomotion in organotypic
spinal cultures (Legrand et al., 2004), this may reﬂect compensa-
tory plasticity changes in glutamate receptor subunit composition
or synaptic density in the developing spinal cord. This point of view
is supported by a seminal work highlighting that long-term NMDA
receptor inhibition affects subunit composition in developing rat
hippocampal neurons (Sinner et al., 2015). As far as botulinum
toxins gain increasing interest in the treatment of neuropathic pain
(Marinelli et al., 2012; Marino et al., 2014; Pavone and Ueda, 2014),
this hypothesis needs to be addressed in further research projects.
4.2. In vitro testing of botulinum toxin B
Our data showed signiﬁcant effects of botulinum toxin B upon
muscle activity in organotypic spinal cord–muscle tissue co-
cultures. However, intrinsic muscle activity is driven by spinal cord
activity and complex motoneuronal network activity. This fact is
reﬂected by the high range of the 5th to 95th percentiles. To
establish an alternative potency testing method for botulinum
toxin B, further studies should aim to use organotypic spinal cord–
muscle tissue co-cultures as an in vitro kit and should measure the
amount of the substrate of botulinum toxin B VAMP-2 as a read-out
using Western blot analysis (Pellett et al., 2007).
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Appendix A. Video data
Video data associated with this article can be found, in the
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